Coloplast A/S stock sinks nearly 8% as Medicare reimbursement change hits Kerecis outlook
Coloplast A/S shares fell 7.82% to 495.35 crowns in Copenhagen after the company slashed its Kerecis growth forecast to 10% due to new U.S. Medicare reimbursement rules. Group revenue for the quarter was flat at 7,043 million crowns, with EBIT before special items down 3% to 1,850 million. Coloplast will phase out Kerecis Shield in Medicare outpatient care and shift focus to its MariGen range.
